Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report

Gynecologic Oncology

Volumn 62, Issue 1, 1996, Pages 4-6

  Markman, Maurie ^a   Iseminger, Karen A ^b   Hatch, Kenneth D ^c   Creasman, William T ^d   Barnes M, Willard ^e   Dubeshter, Brent ^f  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030201090     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0181     Document Type: Article

References (19)

1. 1. Cannistra, S. A. Cancer of the ovary, N. Engl. J. Med. 329, 1550-1559 (1993).
2. 2. Jolles, B. Progesterone in the treatment of advanced malignant tumours of breast, ovary and uterus, Br. J. Cancer 16, 209-221 (1962).
3. 3. Geisler, H. E. Megestrol acetate for the palliation of advanced ovarian carcinoma, Obstet. Gynecol. 61, 95 (1983).
4. 4. Hamerlynck, J. V. Th. H., Maskens, A. P., Mangioni, C., Van Der Burg, M. E. L., Wils, A. M. J., Vermorken, J. B., and Rotmensz, N. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC Gynecological Cancer Cooperative Group Study, Gynecol. Oncol. 22, 313-316 (1985).
5. 5. Markman, M., and Hoskins, W. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population, J. Clin. Oncol. 10, 513-514 (1992).
6. 6. Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., and Lewis, J. L., Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J. Clin. Oncol. 9, 389-393 (1991).
7. 7. Gershenson, D. M., Kavanagh, J. J., Copeland, L. J., Stringer, C. A., Morris, M., and Wharton, J. T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy, Obstet. Gynecol. 73, 798-802 (1989).
8. 8. Gore, M. E., Fryatt, I., Wiltshaw, E., and Dawson, T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds, Gynecol. Oncol. 36, 207-211 (1990).
9. 9. Hoskins, P. J., O'Reilly, S. E., and Swenerton, K. D. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: Relevance to therapy and new drug testing, Int. J. Gynecol. Cancer 1, 205-208 (1991).
10. 10. Hatch, K. D., Beecham, J. B., Blessing, J. A., and Creasman, W. T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: A Gynecologic Oncology Group study of second-line therapy in 105 patients, Cancer 68, 269-271 (1991).
11. 11. Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., and Barrett, R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study, J. Clin. Oncol. 12, 1748-1753 (1994).
12. 12. Ahlgren, J. D., Ellison, N. M., Gottlieb, R. J., Laluna, F., Lokich, J. J., Sinclair, P. R., Ueno, W., Wampler, G. L., Yeung, K-Y., Alt, D., and Fryer, J. G. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program, J. Clin. Oncol. 11, 1957-1968 (1993).
13. 13. Vergote, I., Himmelmann, A., Frankendal, B., Scheistroen, M. M., Vlachos, K., and Trope, C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer, Gynecol. Oncol. 47, 282-286 (1992).
14. 14. Moore, D. H., Valea, F., Crumpler, L. S., and Fowler, W. C., Jr. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma, Gynecol. Oncol. 51, 109-112 (1993).
15. 15. Sutton, G. P., Blessing, J. A., Homesley, H. D., Berman, M. L., and Malfetano, J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study, J. Clin. Oncol. 7, 1672-1676 (1989).
16. 16. Markman, M., Hakes, T., Reichman, B., Lewis, J. L., Jr., Rubin, S., Jones, W., Almadrones, L., Pizzuto, F., and Hoskins, W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease, J. Clin. Oncol. 10, 243-248 (1992).
17. 17. Reed, E., Jacob, J., Ozols, R. F., Young, R. C., and Allegra, C. 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma, Gynecol. Oncol. 46, 326-329 (1992).
18. 18. Look, K. Y., Blessing, J. A., Muss, H. B., and DeGeest, K. 5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: A phase II trial of the Gynecologic Oncology Group, Am. J. Clin. Oncol. 15, 494-496 (1992).
19. 19. Long, III, H. J., Nelimark, R. A., Su, J. Q., Graneau, S. C., Levitt, R., Goldberg, R. M., Poon, M. A., and Kugler, J. W. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma, Gynecol. Oncol. 54, 180-183 (1994).